BZAD01

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 563144

CAS#: 305339-41-7

Description: BZAD01 is a GluN2B subtype-selective NMDA antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

BZAD01 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 563144
Name: BZAD01
CAS#: 305339-41-7
Chemical Formula: C16H12F6N2O
Exact Mass: 362.0854
Molecular Weight: 362.27
Elemental Analysis: C, 53.05; H, 3.34; F, 31.47; N, 7.73; O, 4.42


Synonym: BZAD01; BZAD-01; BZAD 01;

IUPAC/Chemical Name: 4-(Trifluoromethoxy)-N-[2-(trifluoromethyl)benzyl]benzene-carboximidamide

InChi Key: YGOCAMFQDLFNQK-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H12F6N2O/c17-15(18,19)13-4-2-1-3-11(13)9-24-14(23)10-5-7-12(8-6-10)25-16(20,21)22/h1-8H,9H2,(H2,23,24)

SMILES Code: N=C(C1=CC=C(OC(F)(F)F)C=C1)NCC2=CC=CC=C2C(F)(F)F


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934.99.03.00


References

1: Beinat C, Banister SD, Hoban J, Tsanaktsidis J, Metaxas A, Windhorst AD, Kassiou M. Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. Bioorg Med Chem Lett. 2014 Feb 1;24(3):828-30. doi: 10.1016/j.bmcl.2013.12.087. Epub 2013 Dec 28. PubMed PMID: 24412068.

2: Warraich ST, Allbutt HN, Billing R, Radford J, Coster MJ, Kassiou M, Henderson JM. Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Res Bull. 2009 Feb 16;78(2-3):85-90. doi: 10.1016/j.brainresbull.2008.08.023. Epub 2008 Sep 24. PubMed PMID: 18822357.

3: Leaver KR, Allbutt HN, Creber NJ, Kassiou M, Henderson JM. Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clin Exp Pharmacol Physiol. 2008 Nov;35(11):1388-94. doi: 10.1111/j.1440-1681.2008.05046.x. PubMed PMID: 18785982.